• Markets
  • icon
  • Companies
CU6 · ASX

Clarity Pharmaceuticals Ltd. (ASX:CU6)

AU$2.64

 -0.06 (-2.222%)
ASX:Live
15/04/2024 03:09:03 PM
HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

CU6 Overview

CU6 Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Neutral

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Neutral

About CU6

Website

N/A

Telephone

Address

Description

Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.

CU6 Price Chart

Key Stats

Market Cap

AU$737.39M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.67 - 3.05

Trade Value (12mth)

AU$153,924.00

1 week

-2.53%

1 month

2.2%

YTD

28.36%

1 year

289.7%

All time high

3.05053

Key Fundamentals

EPS 3 yr Growth

248.500%

EBITDA Margin

N/A

Operating Cashflow

-$27m

Free Cash Flow Return

-34.10%

ROIC

-30.50%

Interest Coverage

N/A

Quick Ratio

10.20

Other Data

Shares on Issue (Fully Dilluted)

263m

HALO Sector

Next Company Report Date

21-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

CU6 Announcements

Latest Announcements

Date Announcements

15 April 24

Change in substantial holding - Cabbit Pty Ltd

×

Change in substantial holding - Cabbit Pty Ltd

15 April 24

Ceasing to be a substantial holder - Taylor

×

Ceasing to be a substantial holder - Taylor

15 April 24

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

15 April 24

Cleaning Notice

×

Cleaning Notice

08 April 24

Cleansing Notice

×

Cleansing Notice

05 April 24

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

04 April 24

Despatch of Retail Entitlement Offer Booklet

×

Despatch of Retail Entitlement Offer Booklet

04 April 24

Clarity enters into Clinical Supply Agreement

×

Clarity enters into Clinical Supply Agreement

28 March 24

Completion of Placement and Institutional Entitlement Offer

×

Completion of Placement and Institutional Entitlement Offer

26 March 24

Clarity launches $121 million equity raise

×

Clarity launches $121 million equity raise

26 March 24

Investor Presentation

×

Investor Presentation

26 March 24

Proposed issue of securities - CU6

×

Proposed issue of securities - CU6

26 March 24

Cleansing Notice

×

Cleansing Notice

25 March 24

Trading Halt

×

Trading Halt

22 March 24

First participant treated in the last dose escalation cohort

×

First participant treated in the last dose escalation cohort

21 March 24

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

21 March 24

Cleansing Notice

×

Cleansing Notice

21 March 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

15 March 24

Theranostic prostate cancer trial advances to multi-dose

×

Theranostic prostate cancer trial advances to multi-dose

06 March 24

Additional COBRA trial data results

×

Additional COBRA trial data results

01 March 24

S&P DJI Announces March 2024 Quarterly Rebalance

×

S&P DJI Announces March 2024 Quarterly Rebalance

29 February 24

Appendix 4D

×

Appendix 4D

29 February 24

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

29 February 24

Correction to 2023 Annual Report

×

Correction to 2023 Annual Report

15 February 24

Initial COBRA results

×

Initial COBRA results

CU6 Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.10 -0.09 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.10 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock -46.7 -140.4 1.1 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.06 -0.09 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.05 -0.11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -41.3 -82.5 -54.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A -10.7 -15.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock N/A 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock N/A 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.08 0.36 0.27 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.08 0.36 0.27 Lock Lock Lock
     Growth % Lock Lock Lock Lock 148.5 351.7 -25.8 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 256 248 260 Lock Lock Lock
Basic m Lock Lock Lock Lock 256 248 260 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 13 30 36 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 8.1 -196.0 -117.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -13 -30 -36 Lock Lock Lock
     Growth % Lock Lock Lock Lock -37.3 -119.3 -21.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -14 -30 -36 Lock Lock Lock
     Growth % Lock Lock Lock Lock -37.2 -119.4 -22.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -13 -30 -34 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -3 -6 -10 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -10 -24 -25 Lock Lock Lock
     Growth % Lock Lock Lock Lock -47.0 -132.4 -3.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -8 -13 -27 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -27 3 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 11 87 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -8 -14 -28 Lock Lock Lock
     Growth % Lock Lock Lock Lock -13.0 -74.8 -103.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 19 92 65 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 23 100 77 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -19 -92 -65 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 8 8 Lock Lock Lock
Equity $m Lock Lock Lock Lock 20 92 69 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 20 92 69 Lock Lock Lock
     Growth % Lock Lock Lock Lock 148.5 354.9 -25.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -45.2 -23.8 -32.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -50.4 -25.8 -35.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -95.0 -52.7 -44.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -71.9 -42.2 -30.5 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -54.0 -23.7 -34.1 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.4 3.1 1.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -93.4 -100.1 -94.0 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 10.0 13.3 10.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 10.0 13.3 10.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 84.1 92.8 84.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -341.1 -177.4 -364.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -45.2 -23.8 -32.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -50.4 -25.8 -35.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock N/A 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock N/A -25.8 -35.6 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 4,484.0 12,126.2 10,339.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -4,484.0 -12,126.2 -10,339.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

-0.30%

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CU6 Shortsell

Frequently Asked Questions

The current share price of Clarity Pharmaceuticals Ltd. (CU6:ASX) is AU$2.64.
The 52-week high share price for Clarity Pharmaceuticals Ltd. (CU6:ASX) is AU$3.05.
The 52-week low share price for Clarity Pharmaceuticals Ltd. (CU6:ASX)? is AU$0.67.
Clarity Pharmaceuticals Ltd. (CU6:ASX) does not pay a dividend.
Clarity Pharmaceuticals Ltd. (CU6:ASX) does not pay a dividend.
Clarity Pharmaceuticals Ltd. (CU6:ASX) has a franking level of 0%.
Clarity Pharmaceuticals Ltd. (CU6:ASX) is classified in the Healthcare.
The current P/E ratio for Clarity Pharmaceuticals Ltd. (CU6:ASX) is .